LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Combination With Transarterial Chemoembolization (TACE) Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma

Press/Media

Period17 Sep 2024

Media coverage

1

Media coverage

  • TitleLENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Combination With Transarterial Chemoembolization (TACE) Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma
    Media name/outletContify Life Science News
    Country/TerritoryIndia
    Date17/09/24
    PersonsJosep Llovet
View all 1
View less